New AI Tool Accelerates Disease Treatments

University of Virginia School of Medicine scientists have created a computational tool to accelerate the development of new disease treatments. The tool goes beyond current artificial intelligence (AI) approaches by identifying not just which patient populations may benefit but also how the drugs work inside cells.

The researchers have demonstrated the tool's potential by identifying a promising candidate to prevent heart failure, a leading cause of death in the United States and around the world.

The new AI tool called LogiRx, can predict how drugs will affect biological processes in the body, helping scientists understand the effects the drugs will have other than their original purpose. For example, the researchers found that the antidepressant escitalopram, sold as Lexapro, may prevent harmful changes in the heart that lead to heart failure, a condition that causes almost half of all cardiovascular deaths in the United States.

"AI needs to move from detecting patterns to generating understanding," said UVA's Jeffrey J. Saucerman. PhD. "Our LogiRx tool helps us identify not just which drugs can be repurposed for heart disease but how they work in the heart."

Heart failure kills more than 400,000 Americans every year. One of its hallmarks is the overgrowth of cells that thicken the heart muscle and prevent the organ from pumping blood as it should. This is known as cardiac hypertrophy.

Saucerman and his team, led by PhD student Taylor Eggertsen, wanted to see if LogiRx could identify drugs with the potential to prevent cardiac hypertrophy and, ultimately, head off heart failure. They used the tool to evaluate 62 drugs that had been previously identified as promising candidates for the task. LogiRx was able to predict "off-target" effects for seven of these drugs that could help prevent harmful cellular hypertrophy, which were confirmed in cells for two of the drugs.

The scientists then evaluated LogiRx’s predictions by doing lab tests and by looking at outcomes in patients taking the drugs. The latter revealed that patients taking escitalopram were significantly less likely to develop cardiac hypertrophy.

"LogiRx identifies unexpected new uses for old drugs that are already shown to be safe in humans," said Eggertsen, in UVA's Department of Biomedical Engineering, a joint program of the School of Medicine and School of Engineering. "This tool can help researchers explore new patient populations that could benefit from a drug or to avoid unwanted side effects."

Additional lab research and clinical trials will be needed before doctors might start prescribing escitalopram for heart health. But Saucerman is excited about the potential of LogiRx for advancing and accelerating new treatments not just for cardiac hypertrophy but for a host of other serious medical conditions.

"AI is accelerating many aspects of drug development, but it has made less progress in providing the required understanding of how these drug work in the body," Saucerman said. "LogiRx is a step towards combining AI with existing knowledge of how cells work to find new uses for old drugs."

Eggertsen TG, Travers JG, Hardy EJ, Wolf MJ, McKinsey TA, Saucerman JJ.
Logic-based machine learning predicts how escitalopram attenuates cardiomyocyte hypertrophy.
Proc Natl Acad Sci U S A. 2025 Mar 11;122(10):e2420499122. doi: 10.1073/pnas.2420499122

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...